Elvitegravir is primarily used in the treatment of HIV infection. It is an integrase inhibitor, which means it works by blocking the action of integrase, an enzyme that the HIV virus needs to multiply. This helps to reduce the amount of HIV in the body, thereby improving the immune system and reducing the risk of complications from the disease.

Elvitegravir is often prescribed as part of a combination therapy, typically included in a single tablet regimen along with other antiretroviral agents such as cobicistat, emtricitabine, and tenofovir. This combination simplifies the treatment regimen, making it easier for patients to adhere to their medication schedule.

The use of elvitegravir is particularly beneficial for patients who have not responded well to other HIV treatments or for those who are starting therapy for the first time. It is also used in the management of HIV in patients with certain co-infections, such as hepatitis B or C, under the guidance of a healthcare provider.

Overall, elvitegravir plays a crucial role in the effective management of HIV, helping to improve the quality of life for patients and reducing the risk of transmission to others.